The purpose of this study is to validate an integrated pharmacokinetic-pharmacodynamic model
to administer propofol in obese patients.
Our hypothesis is that pharmacokinetic and pharmacodynamic changes occur with increasing
weight and that mathematical models to administer drugs in obese patients can be developed to
accurately predict dose schemes in this population.